Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
12 hedge funds and large institutions have $604K invested in Immune Pharmaceuticals Inc. in 2014 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
33% more funds holding
Funds holding: 9 → 12 (+3)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
48% less capital invested
Capital invested by funds: $1.15M → $604K (-$549K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IFS
Ifrah Financial Services
Little Rock,
Arkansas
|
+$56.3K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$27.4K |
| 3 |
SIM
Spark Investment Management
New York
|
+$5.38K |
| 4 |
Goldman Sachs
New York
|
+$4.3K |
| 5 |
Citigroup
New York
|
+$914 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$27.1K |
| 2 |
EEG
E.E. Geduld
|
-$13.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PRCM
1
Pine River Capital Management
Minnetonka,
Minnesota
| $286K | – | – | – |
|
|
EEG
2
E.E. Geduld
| $66K | -$13.4K | -250 | -13% |
|
|
3
Goldman Sachs
New York
| $62K | +$4.3K | +80 | +5% |
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $42K | – | – | – |
|
|
IFS
5
Ifrah Financial Services
Little Rock,
Arkansas
| $40K | +$56.3K | +1,048 | New |
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $38K | – | – | – |
|
|
BPCE
7
Bank Pictet & Cie (Europe)
Frankfurt Am Main,
Germany
| $25K | – | – | – |
|
|
SIM
8
Spark Investment Management
New York
| $25K | +$5.38K | +100 | +17% |
|
|
ARTA
9
A.R.T. Advisors
New York
| $19K | +$27.4K | +510 | New |
|
|
10
Citigroup
New York
| $1K | +$914 | +17 | New |
|
|
11
Morgan Stanley
New York
| – | -$27.1K | -504 | -99% |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$3K | -44 | Closed |
|
13
Creative Planning
Overland Park,
Kansas
| – | +$54 | +1 | New |
|
IMNP Hedge Fund Activity: Q4 2014 in Review
12 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q4 2014, worth a combined $604K — down 48% from $1.15M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IMNP positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Ifrah Financial Services, opening a new position worth an estimated $56.3K. The largest seller was Morgan Stanley, cutting an estimated $27.1K.
- 12 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q4 2014, up from 9 in Q3 2014.
- Funds reported $604K of Immune Pharmaceuticals Inc. stock for Q4 2014, down 48% quarter-over-quarter.
- 4 funds opened new Immune Pharmaceuticals Inc. positions in Q4 2014 and 1 closed out, a net change of +3 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q4 2014 was Ifrah Financial Services, an estimated $56.3K added.
- The largest Immune Pharmaceuticals Inc. seller in Q4 2014 was Morgan Stanley, an estimated $27.1K sold.
Based on aggregated 13F filings for Q4 2014.